参考文献/References:
[1] Goldblatt H,Lynch J,Hanzal RF,et al. Studies on experimental hypertension: Ⅰ. The production of persistent elevation of systolic blood pressure by means of renal ischemia[J]. J Exp Med,1934,59(3):347-379.
[2] Solandt DY,Nassim R,Cowan CR. Hypertensive effect of blood from hypertensive dogs[J]. Lancet,1940,235(6089):873-874.
[3] Basso N,Terragno NA. History about the discovery of the renin-angiotensin system[J]. Hypertension,2001,38(6):1246-1249.
[4] Grüntzig A,Kuhlmann U,Vetter W,et al. Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis[J]. Lancet Lond Engl,1978,1(8068):801-802.
[5] van Jaarsveld BC,Krijnen P,Pieterman H,et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group[J]. N Engl J Med,2000,342(14):1007-1014.
[6] Bax L,Woittiez AJJ,Kouwenberg HJ,et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function:a randomized trial[J]. Ann Intern Med,2009,150(12):840-848,W150-W151.
[7] ASTRAL Investigators,Wheatley K,Ives N,et al. Revascularization versus medical therapy for renal-artery stenosis[J]. N Engl J Med,2009,361(20):1953-1962.
[8] Cooper CJ ,Murphy TP,Cutlip DE,et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis[J]. N Engl J Med,2014,370(1):13-22.
[9] Bhalla V,Textor SC,Beckman JA,et al. Revascularization for renovascular disease:a scientific statement from the American Heart Association[J]. Hypertension,2022,79(8):e128-e143.
[10] Boden WE,O’Rourke RA,Teo KK,et al. Optimal medical therapy with or without PCI for stable coronary disease[J].?N Engl J Med,2007,356(15):1503-1516.
[11] BARI 2D Study Group,Frye RL,August P,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease[J].?N Engl J Med,2009,360(24):2503-2515.
[12] Al-Lamee R,Thompson D,Dehbi HM,et al. Percutaneous coronary intervention in stable angina (ORBITA):a double-blind,randomised controlled trial[J]. Lancet,2018,391(10115):31-40.
[13] Maron DJ,Hochman JS,Reynolds HR,et al. Initial invasive or conservative strategy for stable coronary disease[J].?N Engl J Med,2020,382(15):1395-1407.
[14] Rajkumar CA,Foley MJ,Ahmed-Jushuf F,et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina[J].?N Engl J Med,2023,389(25):2319-2330.
[15] Zimmermann FM,Ferrara A,Johnson NP,et al. Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis:15-year follow-up of the DEFER trial[J].?Eur Heart J,2015,36(45):3182-3188.
[16] Tonino PA,de Bruyne B,Pijls NH,et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J].?N Engl J Med,2009,360(3):213-224.
[17] de Bruyne B,Pijls NH,Kalesan B,et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease[J].?N Engl J Med,2012,367(11):991-1001.
[18] Fearon WF,Zimmermann FM,de Bruyne B,et al. Fractional flow reserve-guided PCI as compared with coronary bypass surgery[J].?N Engl J Med,2022,386(2):128-137.
[19] Xu B,Tu S,Song L,et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China):a multicentre,randomised,sham-controlled trial[J].?Lancet,2021,398(10317):2149-2159.
[20] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J].?Lancet,2009,373(9671):1275-1281.
[21] Symplicity HTN-2 Investigators,Esler MD,Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial[J].?Lancet,2010,376(9756):1903-1909.
[22] Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J].?N Engl J Med,2014,370:1393-1401.
[23] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J].?Lancet,2017,390(10108):2160-2170.
[24] Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J].?Lancet,2018,391(10137):2346-2355.
[25] Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre,international,single-blind,randomised,sham-controlled trial[J].?Lancet,2018,391(10137)2335-2345.
[26] Azizi M,Sanghvi K,Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised,multicentre,single-blind,sham-controlled trial[J].?Lancet,2021,397(10293):2476-2486.
[27] Nawar K,Mohammad A,Johns EJ,et al. Renal denervation for atrial fibrillation:a comprehensive updated systematic review and meta-analysis[J]. J Hum Hypertens,2022,36(10):887-897.
[28] Fukuta H,Goto T,Wakami K,et al. Effects of catheter-based renal denervation on heart failure with reduced ejection fraction:a meta-analysis of randomized controlled trials[J].?Heart Fail Rev,2022,27(1):29-36.
[29] Kresoja KP,Rommel KP,Fengler K,et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction[J].?Circ Heart Fail,2021,14(3):e007421.
[30]Rey-García J,Townsend RR. Renal denervation:a review[J].Am J Kidney Dis,2022,80(4):527-535.
[31] Wallbach M,Born E,Kampfer D,et al. Long-term effects of baroreflex activation therapy:2-year follow-up data of the BAT Neo system[J]. Clin Res Cardiol. 2020,109(4):513-522.
[32] van Kleef MEAM,Devireddy CM,van der Heyden J,et al. Treatment of resistant hypertension with endovascular baroreflex amplification:3-year results from the CALM-FIM study[J]. JACC Cardiovasc Interv,2022,15(3):321-332.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(3):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(3):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(3):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(3):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(3):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(3):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]